More bad news for Prempro
Executive Summary
Preliminary analysis from the Women's Health Initiative Memory Study evaluating the use of estrogen plus progestin on the development of dementia and mild cognitive impairment suggests negative results. "In contrast to previous work that suggested a beneficial effect on memory and cognition, the preliminary analyses of this arm of WHIMS suggest certain negative findings in a small percentage of the study participants," Wyeth said. An earlier National Institutes of Health-funded study found Wyeth's Premarin (conjugated estrogens) had no effect in the treatment of Alzheimer's disease (1"The Pink Sheet" Feb. 8, 2000, p. 8)...
You may also be interested in...
Premarin Alzheimer's Prevention Studies Urged; Treatment Trial Negative
A trial finding no effect for Premarin in the treatment of Alzheimer's does not rule out a role for estrogen replacement therapy in prevention of the disease, Wyeth-Ayerst and the study authors pointed out.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.